Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea.

PubWeight™: 2.13‹?› | Rank: Top 2%

🔗 View Article (PMC 3565429)

Published in Clin Gastroenterol Hepatol on May 18, 2012

Authors

Banny S Wong1, Michael Camilleri, Paula Carlson, Sanna McKinzie, Irene Busciglio, Olga Bondar, Roy B Dyer, Jesse Lamsam, Alan R Zinsmeister

Author Affiliations

1: Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.

Articles citing this

Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2015) 2.13

Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil (2014) 2.11

RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol Gastrointest Liver Physiol (2014) 2.10

Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2013) 1.20

Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol (2013) 1.12

Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy. Clin Exp Gastroenterol (2014) 0.99

Bovine immunoglobulin protein isolates for the nutritional management of enteropathy. World J Gastroenterol (2014) 0.92

Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol (2013) 0.91

Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol (2014) 0.90

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation. J Neurogastroenterol Motil (2014) 0.88

Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea. Am J Gastroenterol (2016) 0.87

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest (2013) 0.83

Dietary requirement for serum-derived bovine immunoglobulins in the clinical management of patients with enteropathy. Dig Dis Sci (2014) 0.82

Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol (2013) 0.81

Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. Am J Physiol Gastrointest Liver Physiol (2015) 0.81

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clin Transl Gastroenterol (2016) 0.80

Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. Am J Physiol Gastrointest Liver Physiol (2013) 0.80

Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver (2015) 0.79

Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption. Clin Gastroenterol Hepatol (2016) 0.78

Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol (2014) 0.78

Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions. Am J Physiol Gastrointest Liver Physiol (2016) 0.77

Chronic intermittent psychological stress promotes macrophage reverse cholesterol transport by impairing bile acid absorption in mice. Physiol Rep (2015) 0.77

Dietary Triggers in Irritable Bowel Syndrome: Is There a Role for Gluten? J Neurogastroenterol Motil (2016) 0.77

The Farnesoid X Receptor: Good for BAD. Cell Mol Gastroenterol Hepatol (2016) 0.76

Commentary: fibroblast growth factor 19 in patients with bile acid diarrhoea. Aliment Pharmacol Ther (2013) 0.75

Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications. Clujul Med (2014) 0.75

What is irritable bowel syndrome? Therap Adv Gastroenterol (2012) 0.75

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol (2015) 0.75

Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology (2016) 0.75

Faecal biomarker patterns in patients with symptoms of irritable bowel syndrome. Frontline Gastroenterol (2016) 0.75

Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord (2015) 0.75

Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget (2016) 0.75

Bile acids potentiate proton-activated currents in Xenopus laevis oocytes expressing human acid-sensing ion channel (ASIC1a). Physiol Rep (2017) 0.75

[Is the colon oversalted in irritable bowel syndrome?]. Z Gastroenterol (2014) 0.75

Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel) (2017) 0.75

The Effect of Deoxycholic Acid on Secretion and Motility in the Rat and Guinea Pig Large Intestine. J Neurogastroenterol Motil (2017) 0.75

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol (2017) 0.75

Performance characteristics of serum C4 and FGF19 measurements to exclude the diagnosis of bile acid diarrhoea in IBS-diarrhoea and functional diarrhoea. Aliment Pharmacol Ther (2017) 0.75

Articles cited by this

AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76

Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2009) 2.73

Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med (1969) 2.40

A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol (2009) 2.25

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87

Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest (1997) 1.75

Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil (2009) 1.62

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53

Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther (2007) 1.47

Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol (2011) 1.33

Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol (1996) 1.31

High body mass alters colonic sensory-motor function and transit in humans. Am J Physiol Gastrointest Liver Physiol (2008) 1.22

A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology (2011) 1.22

Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr (2008) 1.21

Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol (2001) 1.20

Accelerated regional bowel transit and overweight shown in idiopathic bile acid malabsorption. Am J Gastroenterol (2004) 1.15

75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit. Gut (1987) 1.12

Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther (2009) 1.10

Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol (2008) 1.07

Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol (2006) 1.04

Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol (2003) 1.03

Absence of histopathological changes of ileum and colon in functional chronic diarrhea associated with bile acid malabsorption, assessed by SeHCAT test: a prospective study. Am J Gastroenterol (1994) 0.99

Role of fat maldigestion in pathogenesis of steatorrhea in ileal resection. Fat digestion after two sequential test meals with and without cholestyramine. Gastroenterology (1976) 0.96

Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut (2005) 0.93

Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res (1995) 0.92

Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci (2012) 0.90

Ethanol has an acute effect on bile acid biosynthesis in man. FEBS Lett (1991) 0.89

Impact of bile acid malabsorption on steatorrhoea and symptoms in patients with chronic diarrhoea. Eur J Gastroenterol Hepatol (2000) 0.88

Bile acid malabsorption in patients with chronic diarrhoea. Scand J Gastroenterol (1993) 0.86

Articles by these authors

Functional gastroduodenal disorders. Gastroenterology (2006) 8.51

AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76

Chronic constipation. N Engl J Med (2003) 4.58

Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19

The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92

Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83

Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med (2010) 3.78

Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73

Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65

A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56

Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50

Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81

The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65

Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64

Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63

Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52

Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48

Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47

Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44

Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41

Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30

Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30

A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30

Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14

Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07

Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97

The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94

Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93

Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90

Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90

Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89

Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88

Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87

Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86

Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86

Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86

Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85

Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84

Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82

Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80

Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80

The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77

Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics (2003) 1.76

A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75

Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70

Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol (2006) 1.70

Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69

Increasing incidence of celiac disease in a North American population. Am J Gastroenterol (2013) 1.69

A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66

Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol (2003) 1.66

A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol (2005) 1.64

Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58

Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol (2007) 1.56

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54

Continuous 12-lead electrocardiographic monitoring in an emergency department chest pain unit: an assessment of potential clinical effect. Ann Emerg Med (2003) 1.54

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology (2010) 1.53

KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet (2006) 1.53

Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52

Symptoms and quality of life in community women with fecal incontinence. Clin Gastroenterol Hepatol (2006) 1.52

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52

Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51

Factors that predict relief from upper abdominal pain after cholecystectomy. Clin Gastroenterol Hepatol (2011) 1.50

Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol (2012) 1.47

A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Am J Gastroenterol (2009) 1.47

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes (2007) 1.47

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol (2011) 1.47

Gastric sensory and motor dysfunction in adolescents with functional dyspepsia. J Pediatr (2005) 1.46